Fecal calprotectin levels used as a noninvasive method for screening for chronic gastritis in pediatric patients. A descriptive study
Keywords:
Child, Gastritis, Leukocyte L1 antigen complexAbstract
BACKGROUND: Gastritis consists of inflammation of the gastric mucosa and is one of the main causes of dyspeptic symptoms in children. OBJECTIVE: To investigate the presence of inflammation by evaluating fecal calprotectin (FC) in children diagnosed with chronic gastritis. DESIGN AND SETTING: Descriptive study in Pediatric Gastroenterology Department of Ondokuz Mayis University Hospital in Turkey. METHODS: Between January 2016 and July 2018, FC levels were compared retrospectively in children with chronic gastritis (histopathology-based diagnosis), patients with inflammatory bowel disease (IBD) and healthy children. RESULTS: A total of 67 chronic gastritis patients (61.2% girls) with a mean age of 13.09 ± 3.5 years were evaluated. The mean FC levels were 153.4 μg/g in the chronic gastritis group, 589.7 μg/g in the IBD group and 43.8 μg/g in the healthy group. These levels were higher in chronic gastritis patients than in healthy individuals (P = 0.001) and higher in IBD patients than in the other two groups (P < 0.001). The FC level in the patients with chronic active gastritis (156.3 μg/g) was higher than in those with chronic inactive gastritis (150.95 μg/g) (P = 0.011). Among the patients with chronic active gastritis, the FC level was significantly higher in Helicobacter pylori-positive individuals than in negative individuals (P = 0.031). CONCLUSION: We confirmed the association between increased FC and chronic gastritis. Elevated FC levels may be seen in patients with chronic active gastritis. In order to be able to use FC as a screening tool for chronic gastritis, further studies in a larger study group are needed.
Downloads
References
Sierra D, Wood M, Kolli S, Felipez LM. Pediatric Gastritis, Gastropathy, and Peptic Ulcer Disease. Pediatr Rev. 2018;39(11):542-9. PMID: 30385583; https://doi.org/10.1542/pir.2017-0234
Sipponen P, Maaroos HI. Chronic gastritis. Scand J Gastroenterol. 2015;50(6):657-67. PMID: 25901896; https://doi.org/10.3109/00365521.2015.1019918
Feldman M, Jensen PJ. Gastritis etiology and diagnosis. In: Lamont JT, Grover S, editors. UpToDate; 2021. Available from: https://www.uptodate.com/contents/gastritis-etiology-and-diagnosis Accessed in 2021 (Jun 30).
Allen A, Leonard AJ, Sellers LA. The mucus barrier. Its role in gastroduodenal mucosal protection. J Clin Gastroenterol. 1988;10 Suppl 1:S93-8. PMID: 3053885.
Fagerberg UL, Lööf L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45(4):414-20. PMID: 18030206; https://doi.org/10.1097/MPG.0b013e31810e75a9
Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016;9:21-9. PMID: 26869808; https://doi.org/10.2147/CEG.S51902
Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016;9:21-9. PMID: 26869808; https://doi.org/10.2147/CEG.S51902
Montalto M, Gallo A, Santoro L, D’Onofrio F, Landolfi R, Gasbarrini A. Role of fecal calprotectin in gastrointestinal disorders. Eur Rev Med Pharmacol Sci. 201317(12):1569-82. PMID: 23832721.
Vaos G, Kostakis ID, Zavras N, Chatzemichael A. The role of calprotectin in pediatric disease. Biomed Res Int. 2013;2013:542363. PMID: 24175291; https://doi.org/10.1155/2013/542363
Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007;119(6):1113-9. PMID: 17545378; https://doi.org/10.1542/peds.2006-1865
Fallahi G, Motamed F, Yousefi A, et al. The effect of probiotics on fecal calprotectin in patients with cystic fibrosis. Turk J Pediatr. 2013;55(5):475-8. PMID: 24382526.
Levine A, Koletzko S, Turner D, et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795-806. PMID: 24231644; https://doi.org/10.1097/MPG.0000000000000239
Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161-81. PMID: 8827022; https://doi.org/10.1097/00000478-199610000-00001
Genta RM, Sonnenberg A. Helicobacter-negative gastritis: a distinct entity unrelated to Helicobacter pylori infection. Aliment Pharmacol Ther. 2015;41(2):218-26. PMID: 25376264; https://doi.org/10.1111/apt.13007
Sipponen P, Maaroos HI. Chronic gastritis. Scand J Gastroenterol. 2015;50(6):657-67. PMID: 25901896; https://doi.org/10.3109/00365521.2015.1019918
Bacha D, Walha M, Ben Slama S, et al. Chronic gastritis classifications. Tunis Med. 2018;96(7):405-10. PMID: 30430483.
Manz M, Burri E, Rothen C, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol. 2012;12:5. PMID: 22233279; https://doi.org/10.1186/1471-230X-12-5
Montalto M, Gallo A, Ianiro G, et al. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol. 2010;16(27):3406-10. PMID: 20632443; https://doi.org/10.3748/wjg.v16.i27.3406
Sýkora J, Huml M, Siala K, et al. Paediatric Rome III Criteria-Related Abdominal Pain Is Associated With Helicobacter pylori and Not With Calprotectin. J Pediatr Gastroenterol Nutr. 2016;63(4):417-22. PMID: 26913755; https://doi.org/10.1097/MPG.0000000000001172
Kotze LM, Nisihara RM, Marion SB, Cavassani MF, Kotze PG. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Arq Gastroenterol. 2015;52(1):50-4. PMID: 26017083; https://doi.org/10.1590S0004-28032015000100011
Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(2):199-205. PMID: 18618670; https://doi.org/10.1002/ibd.20535
Pathirana WGW, Chubb SP, Gillett MJ, Vasikaran SD. Faecal Calprotectin. Clin Biochem Rev. 2018;39(3):77-90. PMID: 30828114.
Mehrabani S. Helicobacter pylori Infection in Children: a Comprehensive Review. Maedica (Bucur). 2019;14(3):292-7. PMID: 31798748; https://doi.org/10.26574/maedica.2019.14.3.292
Okuda M, Lin Y, Kikuchi S. Helicobacter pylori Infection in Children and Adolescents. Adv Exp Med Biol. 2019;1149:107-20. PMID: 31037557; https://doi.org/10.1007/5584_2019_361
Talebi Bezmin Abadi A. Diagnosis of Helicobacter pylori Using Invasive and Noninvasive Approaches. J Pathog. 2018;2018:9064952. PMID: 29951318; https://doi.org/10.1155/2018/9064952
Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14(8):841-5. PMID: 12172403; https://doi.org/10.1097/00042737-200208000-00005
Stolte M, Eidt S. Chronic erosions of the antral mucosa: a sequela of Helicobacter pylori-induced gastritis. Z Gastroenterol. 1992;30(12):846-50. PMID: 1481549.
